[go: up one dir, main page]

WO2015184326A8 - Conjugates, particles, compositions, and related methods - Google Patents

Conjugates, particles, compositions, and related methods Download PDF

Info

Publication number
WO2015184326A8
WO2015184326A8 PCT/US2015/033284 US2015033284W WO2015184326A8 WO 2015184326 A8 WO2015184326 A8 WO 2015184326A8 US 2015033284 W US2015033284 W US 2015033284W WO 2015184326 A8 WO2015184326 A8 WO 2015184326A8
Authority
WO
WIPO (PCT)
Prior art keywords
particles
compositions
conjugates
related methods
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/033284
Other languages
French (fr)
Other versions
WO2015184326A1 (en
Inventor
Roy I. CASE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dare Bioscience Inc
Original Assignee
Cerulean Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerulean Pharma Inc filed Critical Cerulean Pharma Inc
Publication of WO2015184326A1 publication Critical patent/WO2015184326A1/en
Publication of WO2015184326A8 publication Critical patent/WO2015184326A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Particles and compositions containing the particles for delivering nucleic acid agents are described herein. Methods of preparing same are also described.
PCT/US2015/033284 2014-05-30 2015-05-29 Conjugates, particles, compositions, and related methods Ceased WO2015184326A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462005353P 2014-05-30 2014-05-30
US62/005,353 2014-05-30

Publications (2)

Publication Number Publication Date
WO2015184326A1 WO2015184326A1 (en) 2015-12-03
WO2015184326A8 true WO2015184326A8 (en) 2016-06-23

Family

ID=54699895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/033284 Ceased WO2015184326A1 (en) 2014-05-30 2015-05-29 Conjugates, particles, compositions, and related methods

Country Status (1)

Country Link
WO (1) WO2015184326A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010249881B2 (en) * 2009-05-16 2015-01-22 Agave Pharma, Incorporated Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
JP5756858B2 (en) * 2010-08-20 2015-07-29 セルリアン・ファーマ・インコーポレイテッド Composites, particles, compositions and related methods
WO2013126564A1 (en) * 2012-02-22 2013-08-29 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
WO2015184326A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
SG10201803042PA (en) Anti-tim-3 antibodies
WO2018109174A3 (en) Il-11 antibodies
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
HK1205751A1 (en) Conjugates, particles, compositions, and related methods
WO2015168019A3 (en) Anti-ptk7 antibody-drug conjugates
MY191581A (en) Anti-pd-1 antibodies
EP3374494A4 (en) Crispr compositions and methods of using the same for gene therapy
WO2018109170A3 (en) Il-11ra antibodies
ZA201707749B (en) Compounds targeting proteins, compositions, methods, and uses thereof
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
WO2016073789A3 (en) Anti-fgfr2/3 antibodies and methods using same
HK1256817A1 (en) Compositions and methods for genome editing
EP4470557A3 (en) Anti-cgrp antibody formulation
WO2016077381A8 (en) Anti-interleukin-33 antibodies and uses thereof
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
WO2015011694A3 (en) Isotopologues of smad7 antisense oligonucleotides
WO2016097370A3 (en) Anti-axl antagonistic antibodies
WO2015179658A3 (en) Anti-gpc3 antibodies and immunoconjugates
WO2018006074A3 (en) Compounds and methods for modulating rna function
EP3200804A4 (en) Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP3129048A4 (en) Antibodies, pharmaceutical compositions and uses thereof
HK1248069A1 (en) Desacetoxytubulysin h and analogs thereof
WO2015191945A3 (en) Solid state forms of sofosbuvir
WO2015200534A3 (en) Small molecule agonists of neurotensin receptor 1
EP4285930A3 (en) Protein formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15800506

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15800506

Country of ref document: EP

Kind code of ref document: A1